General
Preferred name
LINCOMYCIN
Synonyms
Lincomycin HCl ()
NSC 70731 ()
U10149A ()
Lincomycin hydrochloride hydrate ()
LINCOMYCIN HYDROCHLORIDE ()
Lincomycin (hydrochloride) ()
Lincomycin (hydrochloride monohydrate) ()
U-10149 ()
Lincomycin hydrochloride monohydrate ()
Lincomycin ()
Albiotic ()
NSC-70731 ()
NSC-757092 ()
Lincomycin hydrochloride anhdrous ()
Lincomycin (as hydrochloride) ()
Lincolnensin hydrochloride monohydrate ()
Lincolnensin hydrochloride ()
Lincomix ()
Lincocin ()
Lincomycin hydrochloride usp ()
Lincomycine ()
Lincomicina ()
U-10,149 ()
Lincolnensin ()
Lincomycin ()
P&D ID
PD013336
CAS
7179-49-9
154-21-2
859-18-7
17431-82-2
Tags
available
drug
natural product
Approved by
FDA
First approval
1964
Drug indication
Gram-positive bacterial infection
osteomyelitis
Drug Status
approved
vet_approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Lincomycin hydrochloride monohydrate is a narrow-spectrum antibiotic, has similar effects to erythromycin, which has a good effect on gram-positive coccus, mainly used to inhibit the synthesis of bacterial cell protein[1][2].
PHARMACODYNAMICS Lincomycin is a lincosamide antibiotic that produced by Streptomyces lincolnensis. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: Streptococcus pyogenes and Viridans group streptococci; Aerobic gram-positive bacilli: Corynebacterium diphtheriae; Anaerobic gram-positive non-sporeforming bacilli: Propionibacterium acnes; Anaerobic gram-positive sporeforming bacilli: Clostridium tetani and Clostridium perfringens.
ROE Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Biliary excretion is also an important route of excretion.
HALF-LIFE The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life may be prolonged in patients with severe impairment of renal function. Half life may be extended up to 2-fold in patients with hepatic impairment.
DESCRIPTION Lincomycin is a lincosamide antibacterial that has activity against Gram-positive and anaerobic bacteria . It was isolated from the actinomycete Streptomyces lincolnensis. Pathogenic species of bacteria that are sensitive to lincomycin include Streptococcus, Staphylococcus, and Mycoplasma. (GtoPdb)
DESCRIPTION Lincomycin, a lincosamide antibiotic, is an antimicrobial agent used for the research of Gram-positive bacteria infections[1].
PRICE 133
DESCRIPTION Lincomycin (U-10149) is a lincosamide antibiotic from Streptomyces that is effective against most susceptible gram-positive and cell wall-less bacteria and is generally used in patients for whom penicillin is not available.
PRICE 29
DESCRIPTION Lincomycin Hydrochloride(U10149A) is an antibiotic produced by Streptomyces lincolnensis var. lincolnensis.;Target: Antibacterial;Lincomycin hydrochloride is a systemic antibiotic, which is active against most common gram positive bacteria. It has proved to be excellent for infectious diseases like acne, anthrax, pneumonia, and also for the treatment of furunculosis, carbuncles, impetigo, burns and wounds, carrying to gram positive bacteria. Lincomycin hydrochloride inhibits cell growth and microbial protein synthesis, by interacting strongly and specifically with the 50S ribosomal subunit, at mutually related sites [1-3].
DESCRIPTION Lincomycin hydrochloride monohydrate (Lincomycin hydrochloride hydrate) is an antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. (TargetMol Bioactive Compound Library)
DESCRIPTION Lincomycin is an antibiotic indicated only for the treatment of serious infections and is typically reserved for use in cases of penicillin allergy or where penicillin is inappropriate. (Enamine Bioactive Compounds)
DESCRIPTION Lincomycin hydrochloride (U10149A) is a lincosamide antibiotic identified in S.lincolnensis with activity against gram-positive cocci and anaerobic bacteria. (TargetMol Bioactive Compound Library)
Compound Sets
19
Cayman Chemical Bioactives
21526
ChEMBL Approved Drugs
CHEMBL3989551
CHEMBL1447
ChEMBL Drugs
CHEMBL3989551
CHEMBL1447
Drug Repurposing Hub
DrugBank
DB01627
DrugBank Approved Drugs
DB01627
DrugCentral
1582
DrugCentral Approved Drugs
1582
DrugMAP
DMVTHER
DrugMAP Approved Drugs
DMVTHER
Enamine Bioactive Compounds
EBC-13871
Enamine BioReference Compounds
Guide to Pharmacology
10941
MedChem Express Bioactive Compound Library
HY-B1358
HY-117660
HY-B0417A
NCATS Inxight Approved Drugs
BOD072YW0F
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
lincomycin-hydrochloride-monohydrate
TargetMol Bioactive Compound Library
T1235
T1277
External IDs
78
Properties
(calculated by RDKit )
Molecular Weight
406.21
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
5
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
0
cLogP
-0.86
TPSA
122.49
Fraction CSP3
0.94
Chiral centers
9.0
Largest ring
6.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Bacterial
50S ribosome
DNA/RNA Synthesis
Antibiotics,Antibiotics for Mammalian Cell Culture
Indication
enteritis
MOA
bacterial 30S ribosomal subunit inhibitor
Pathway
Microbiology/virology
Anti-infection
Cell Cycle/DNA Damage
Therapeutic Class
Antibiotics
Source data